+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Radiotheranostics - Global Strategic Business Report- Product Image
Radiotheranostics - Global Strategic Business Report- Product Image
New

Radiotheranostics - Global Strategic Business Report

  • PDF Icon

    Report

  • 168 Pages
  • January 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6042767
Description Jump to:
The global market for Radiotheranostics was valued at US$10.4 Billion in 2024 and is projected to reach US$22.4 Billion by 2030, growing at a CAGR of 13.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Radiotheranostics Market - Key Trends & Drivers Summarized

What Is Propelling Radiotheranostics to the Forefront of Precision Medicine?

Radiotheranostics, a cutting-edge approach that combines diagnostic imaging with targeted radiotherapy, is emerging as a game-changer in personalized medicine. This dual-function technology enables precise tumor identification and tailored treatment using radiopharmaceutical agents, minimizing damage to healthy tissues. As cancer prevalence continues to rise globally, radiotheranostics is gaining traction for its ability to provide more effective and less invasive treatment options. Furthermore, the integration of radiotheranostics into nuclear medicine is revolutionizing oncology, offering patients better outcomes and quality of life. The growing shift toward precision medicine is reinforcing its adoption, making radiotheranostics a pivotal tool in the fight against cancer.

How Is Innovation Redefining the Scope of Radiotheranostics?

Technological advancements are playing a central role in expanding the capabilities of radiotheranostics. The development of novel radiopharmaceuticals, such as theranostic isotopes like lutetium-177 and actinium-225, is enabling higher precision in both imaging and therapy. Advances in molecular imaging technologies, including PET/CT and SPECT/CT, are improving the accuracy of disease diagnosis and treatment monitoring. Additionally, artificial intelligence and machine learning are being incorporated into radiotheranostic workflows to enhance imaging interpretation and optimize treatment planning. These innovations are not only driving clinical success but also encouraging pharmaceutical companies and research institutions to invest heavily in radiotheranostics development.

What Are the Emerging Applications and Trends in Radiotheranostics?

The application of radiotheranostics is rapidly expanding beyond oncology, where it has demonstrated remarkable success in treating prostate cancer and neuroendocrine tumors. Researchers are exploring its potential in addressing other diseases, such as cardiovascular conditions and certain infectious diseases, by leveraging its ability to target specific biological pathways. An emerging trend is the use of combination therapies, where radiotheranostics is paired with immunotherapy or chemotherapy to amplify treatment efficacy. Furthermore, advancements in radiopharmaceutical production and supply chain logistics are addressing scalability challenges, ensuring that these therapies are more widely available to patients across diverse healthcare settings.

What Drives the Rapid Growth in the Radiotheranostics Market?

The growth in the Radiotheranostics market is driven by several factors. Increasing cancer incidence worldwide has heightened the need for innovative treatment modalities, making radiotheranostics a critical focus area. Significant advancements in radiopharmaceutical development and molecular imaging technologies have enhanced the efficacy and accessibility of these treatments. Rising investments in nuclear medicine infrastructure and expanding healthcare budgets in developing regions are also accelerating market growth. Additionally, the growing preference for personalized treatment approaches among both patients and healthcare providers is boosting the adoption of radiotheranostics. Regulatory support and favorable reimbursement policies further contribute to the widespread adoption of this promising technology, cementing its role in the future of precision medicine.

Scope of the Study

The report analyzes the Radiotheranostics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments:

Modality (Targeted Diagnostics, Targeted Therapeutics); Radioisotope (Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope, Other Radioisotopes); Application (Oncology Application, Non-Oncology Application).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Targeted Diagnostics Modality segment, which is expected to reach US$9.8 Billion by 2030 with a CAGR of a 7.5%. The Targeted Therapeutics Modality segment is also set to grow at 20.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $2.7 Billion in 2024, and China, forecasted to grow at an impressive 13.0% CAGR to reach $3.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Actinium Pharmaceuticals, Inc., Ariceum Therapeutics, Bayer AG, Cardinal Health, Inc., Curium and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Radiotheranostics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Radiotheranostics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Radiotheranostics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Some of the 36 companies featured in this Radiotheranostics market report include:

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Economic Frontiers: Trends, Trials & Transformations
Radiotheranostics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Focus on Precision Medicine and Targeted Therapies Drives Market Growth
Rising Adoption of Theranostic Agents in Oncology Treatments Propels Industry Expansion
Growing Use of PET Imaging in Radiotheranostic Applications Fuels Demand
Expansion of Nuclear Medicine Facilities Supporting Radiotheranostics Enhances Market Potential
Advancements in Radiolabeling Technologies for Improved Accuracy Propel Technological Growth
Integration of AI Tools in Radiotheranostic Imaging and Diagnostics Drives Innovation
Increasing Demand for Personalized Treatment Protocols in Cancer Care Boosts Adoption Rates
Collaboration Between Pharmaceutical and Diagnostic Companies in Radiotheranostics Drives Market Expansion
Role of Radiotheranostics in Emerging Immuno-Oncology Treatments Fuels New Opportunities
Rising Utilization of Theranostics for Non-Oncological Conditions Enhances Market Demand
Growing Interest in Dual-Modality Imaging Techniques Drives Technological Advancements
Investments in R&D for Novel Radiotheranostic Compounds Propel Industry Innovation
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Radiotheranostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Targeted Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Targeted Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Lutetium-177 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Lutetium-177 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Gallium-68 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Gallium-68 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Iodine-131 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Iodine-131 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Iodine-123 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Other Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Other Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 19: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Non-Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World 6-Year Perspective for Non-Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 22: USA Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 23: USA 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 24: USA Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 25: USA 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
CANADA
TABLE 28: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 29: Canada 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 30: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 31: Canada 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
JAPAN
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 34: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 35: Japan 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 36: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 37: Japan 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
CHINA
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 40: China Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 41: China 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 42: China Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 43: China 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
EUROPE
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 46: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 47: Europe 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 48: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 49: Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 52: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 53: Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
FRANCE
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 54: France Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 55: France 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 56: France Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: France 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 58: France Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 59: France 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
GERMANY
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 60: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 61: Germany 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 62: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Germany 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 64: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 65: Germany 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
ITALY
TABLE 66: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 67: Italy 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 68: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Italy 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 70: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 71: Italy 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
UNITED KINGDOM
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 72: UK Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 73: UK 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 74: UK Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: UK 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 76: UK Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 77: UK 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
REST OF EUROPE
TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 79: Rest of Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Rest of Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 83: Rest of Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
ASIA-PACIFIC
Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 85: Asia-Pacific 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Asia-Pacific 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 89: Asia-Pacific 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
REST OF WORLD
TABLE 90: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 91: Rest of World 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
TABLE 92: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of World 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
TABLE 94: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 95: Rest of World 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
IV. COMPETITION

Companies Mentioned

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

Table Information

Report AttributeDetails
No. of Pages168
PublishedJanuary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 10.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.4 Billion
Compound Annual Growth Rate13.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Radiotheranostics Global Market Report 2024 - Product Image

Radiotheranostics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Radiotheranostic Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Radiotheranostic Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Radiopharmaceuticals - Global Strategic Business Report - Product Image

Radiopharmaceuticals - Global Strategic Business Report

  • Report
  • 739 Pages
  • Global
From
Radiopharmaceutical Theranostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Radiopharmaceutical Theranostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 105 Pages
  • Global
From
Radiopharmaceutical Theranostics Global Market Report 2024 - Product Image

Radiopharmaceutical Theranostics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.